1. Home
  2. CTNM vs HYLN Comparison

CTNM vs HYLN Comparison

Compare CTNM & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • HYLN
  • Stock Information
  • Founded
  • CTNM 2009
  • HYLN 2018
  • Country
  • CTNM United States
  • HYLN United States
  • Employees
  • CTNM N/A
  • HYLN N/A
  • Industry
  • CTNM
  • HYLN Construction/Ag Equipment/Trucks
  • Sector
  • CTNM
  • HYLN Consumer Discretionary
  • Exchange
  • CTNM Nasdaq
  • HYLN Nasdaq
  • Market Cap
  • CTNM 453.0M
  • HYLN 414.9M
  • IPO Year
  • CTNM 2024
  • HYLN N/A
  • Fundamental
  • Price
  • CTNM $17.21
  • HYLN $2.53
  • Analyst Decision
  • CTNM Strong Buy
  • HYLN Hold
  • Analyst Count
  • CTNM 4
  • HYLN 1
  • Target Price
  • CTNM $29.25
  • HYLN $2.00
  • AVG Volume (30 Days)
  • CTNM 74.8K
  • HYLN 963.4K
  • Earning Date
  • CTNM 11-06-2024
  • HYLN 11-19-2024
  • Dividend Yield
  • CTNM N/A
  • HYLN N/A
  • EPS Growth
  • CTNM N/A
  • HYLN N/A
  • EPS
  • CTNM N/A
  • HYLN N/A
  • Revenue
  • CTNM N/A
  • HYLN $96,000.00
  • Revenue This Year
  • CTNM N/A
  • HYLN N/A
  • Revenue Next Year
  • CTNM N/A
  • HYLN N/A
  • P/E Ratio
  • CTNM N/A
  • HYLN N/A
  • Revenue Growth
  • CTNM N/A
  • HYLN N/A
  • 52 Week Low
  • CTNM $13.27
  • HYLN $0.55
  • 52 Week High
  • CTNM $22.00
  • HYLN $2.98
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • HYLN 50.28
  • Support Level
  • CTNM N/A
  • HYLN $2.26
  • Resistance Level
  • CTNM N/A
  • HYLN $2.98
  • Average True Range (ATR)
  • CTNM 0.00
  • HYLN 0.19
  • MACD
  • CTNM 0.00
  • HYLN 0.00
  • Stochastic Oscillator
  • CTNM 0.00
  • HYLN 37.76

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About HYLN Hyliion Holdings Corp.

Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it is also focused on mobile applications, including vehicles and marine technologies. The Company aims to offer innovative, yet practical solutions that contribute positively to the environment in the energy economy.

Share on Social Networks: